Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

3282 - PD-L1 expression and prognosis significance in advanced ovarian cancer


09 Sep 2017


Gynaecological cancers


Ovarian Cancer


Estrid Høgdall


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


E. Høgdall1, C. Høgdall2, T.T. Vo3, W. Zhou3, M. Busch-Sørensen3, S.M. Soerensen4, D. Chappell3, J. Georgsen5, E. Mejlgaard5, L. Nedergaard6, T. Steiniche5

Author affiliations

  • 1 Pathology, Herlev Hospital, University of Copenhagen, 2730 - Herlev/DK
  • 2 Gynaecology And Obstetrics, Rigshospitalet, University of Copenhagen, Copenhagen/DK
  • 3 Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 4 Oncology, Rigshospitalet, University of Copenhagen, Copenhagen/DK
  • 5 Pathology, Aarhus University Hospital, Aarhus/DK
  • 6 Pathology, Rigshospitalet, University of Copenhagen, Copenhagen/DK


Abstract 3282


Recent data suggest that programmed death ligand 1 (PD-L1) expression may predict response to anti–programmed death 1 (PD-1) therapy. This retrospective observational study evaluated the prognostic effect of PD-L1+ expression in patients with histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer (OCa).


Patients diagnosed with FIGO stages II-IV OCa from 2004-2012, at Aarhus University Hospital and Rigshospitalet, Copenhagen, Denmark, were included. PD-L1 expression was measured in tissue collected at OCa surgery, using immunohistochemistry with anti–PD-L1 22C3 antibody. PD-L1+ expression was defined as staining in ≥ 1% of tumor or inflammatory cells. Patients partially sensitive (PPS; treatment-free interval [TFI] of 6-12 mo) or fully sensitive (FPS; TFI >12 mo) to platinum therapy were considered platinum sensitive, whereas those refractory (TFI


Median age of the 376 patients at diagnosis was 63 years (range, 26-86). 77% had histologic grade 2/3 serous adenocarcinoma, 46% had residual tumor after surgery, and 9%, 70%, and 21% had FIGO stages II, III, and IV disease, respectively. FPS, PPS, platinum-resistant, and platinum-refractory disease comprised 49%, 27%, 15%, and 9% of patients, respectively. 50.5% of patients were PD-L1+, with prevalence increasing with increased platinum sensitivity (P for linear trend


PD-L1 was frequently expressed in advanced OCa patients, and expression may be prognostic, particularly in those with partially platinum-sensitive OCa.

Clinical trial identification

Legal entity responsible for the study

Merck & Co., Inc.


Merck & Co., Inc.


T.T. Vo: Employed by, own stock in, and have received research grants from Merck & Co., Inc. W. Zhou, M. Busch-Sørensen, D. Chappell: Employed by and own stock in Merck & Co., Inc. T. Steiniche: Received research funding from and have been reimbursed for travel and accommodation expenses by Merck & Co., Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.